Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | MPI | P34949 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14642602 | 0.86 | ALDH1A1 (0.63) | ATMALDH1A1MAPTCES2PKM | |
| SCHEMBL1252912 | 0.79 | ATM (0.48) | ATMALDH1A1MAPTCES2PKM | |
| SCHEMBL7513064 | 0.74 | ALDH1A1 (0.36) | ATMALDH1A1MAPTCES2PKM | |
| SCHEMBL853674 | 0.72 | MAPT (0.52) | ATMALDH1A1MAPTCES2PKM | |
| SCHEMBL359232 | 0.72 | ATM (0.52) | ATMALDH1A1MAPTCES2PKM | |
| SCHEMBL19074432 | 0.72 | ALDH1A1 (0.42) | ATMALDH1A1MAPTCES2PKM | |
| Methane SCHEMBL21391655 | 0.70 | ATM (0.50) | ATMALDH1A1MAPTCES2PKM | |
| SCHEMBL18876542 | 0.70 | ATM (0.45) | ATMALDH1A1MAPTCES2PKM | |
| SCHEMBL16308964 | 0.68 | ATM (0.48) | ATMALDH1A1MAPTCES2PKM | |
| SCHEMBL6261895 | 0.68 | ATM (0.48) | ATMALDH1A1MAPTCES2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20110086840-A1 | N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | ATM 376/4885ALDH1A1 4303/4885MAPT 349/4885 |
| US-20110086840-A1 | N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | P2RX7, P2RY1, PNP | ATM 1825/4885ALDH1A1 349/4885MAPT 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.